MP 1032

Drug Profile

MP 1032

Alternative Names: MP1032

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator MetrioPharm
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 13 Apr 2016 Phase-II clinical trials in Plaque psoriasis in Germany (PO) (EudraCT2015-005159-28)
  • 29 Mar 2016 MetrioPharm has patent protection for MP 1032 in Europe, USA, Australia and New Zealand (MetrioPharm website, April 2016)
  • 02 Mar 2016 MetrioPharm has patent protection for MP 1032 in China (MetrioPharm website, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top